Stockholm, 6 September 2016. Nuevolution AB (publ) announces its report for the fourth quarter and full year 2015/16. The report is available on the company’s home page (www.nuevolution.com). The following is taken from the quarterly report. Fourth quarter and full year summary · During the fourth quarter of 2015/16, additional pre-clinical studies in Nuevolution’s RORγt inverse agonist (inhibitor) program came out with positive results for its lead and backup candidate. Production of the active pharmaceutical ingredient (API) will commence in September 2016 for the first RORγt inverse agonist candidate. · In the Cytokine X program, proof-of-concept was achieved in a disease relevant mouse model. · In vivo studies are ongoing in the BET inhibitor program and in vitro studies are ongoing in the RORγt agonist program with results of these studies expected in the third and fourth quarter 2016, respectively. · The Janssen Biotech collaboration is proceeding according to schedule. We expect initiation of one additional project within the next six months. · Group revenues for the fourth quarter of 2015/16 amounted to SEK 3.1 (5.6) million. Full year 2015/16: SEK 21.3 (29.8) million. · The fourth quarter of 2015/16 is impacted by significant non-recurring and non-cash expenses for the 2015/21 warrant program of SEK 48.5 million and non -recurring reimbursement of VAT of SEK 2.9 million. Hence, both adjusted and reported figures are shown below. · The adjusted operating loss in the fourth quarter of 2015/16 was SEK -31.2 ( -21.8) million. As reported, the operating loss amounted to SEK -76.7 million ( -21.8). Full year 2015/16: Adjusted operating loss of SEK -91.5 (-64.9) million. As reported, the operating loss was SEK -151.9 million (-64.9), including non -recurring expenses of SEK 60.4 million in expenses for the warrant program and IPO costs of SEK 11.9 million. · The adjusted net loss in the fourth quarter of 2015/16 amounted to SEK -29.1 (-20.0) million. As reported, the net loss was SEK -74.7 million (-20.0). Full -year 2015/16: Adjusted net loss of SEK -84.6 (-54.7) million. As reported, the net loss amounted to SEK -145.0 million (-54.7), including the non-recurring expenses for the IPO and warrant program. · Adjusted earnings per share (EPS) in the fourth quarter of 2015/16 was SEK -0.68 (-0.70), and SEK -1.74 (-0.70) as reported. Full year 2015/16: Adjusted EPS of SEK -2.32 (-2.26), and SEK -3.98 (-2.26) as reported, including non -recurring expenses for the IPO and warrant program. · Net cash at June 30, 2016 was SEK 201.3 (44.0) million. Events occurred after June 30, 2016: On July 1, 2016, an extraordinary shareholder’s meeting (EGM) unanimously resolved to amend the terms and conditions of the company’s incentive program, warrant program 2015/2021, in accordance with the major shareholders’ proposal. The warrant program was expensed in the fourth quarter of 2015/16, as majority pre-approval was obtained prior to the EGM. Message of the CEO “We are pleased with the development of our programs and progress in partnership discussions during the fourth quarter of 2015/16. We continue to expect to enter one or two program licensing agreements and one or two risk-sharing collaborations in the next nine months”, CEO Alex Haahr Gouliaev stated. On Tuesday 6 September at 13:00 CEST, the company’s executive management will host a conference call and webcast discussion of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained as follows: LIVE access on Tuesday 6 September at 13:00 CEST Telephone numbers: SE: +46 85 664 2669 DK: +45 8233 3178 UK: +44 20 3008 9808 US: +1 855 7532 235 Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com REPLAY access Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 3913 0902 Email: ahg@nuevolution.com Henrik Damkjær Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com Information about Nuevolution AB (publ) Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology. This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication on Tuesday 6 September, 08.00 (CEST). Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.
Nuevolution AB (publ) announces its results for the fourth
Top 10 Most Recent News Articles
UAE Trust Model Faces Its Hardest Test During Crisis
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone
Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....
Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst
A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...
Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
Fluence Investors Face a November 27 Litigation Clock
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue ReadingTop 5 Most Recently Viewed Articles
Elis Capital Structure Overview and Voting Rights Update
Elis Capital Structure Overview Elis, a prominent player in the services sector, is committed to providing transparency regarding its capital structure. As of the recent assessment, the company detailed the number of shares that constitute its capital along with the total number of voting rights. Share Capital and Voting Rights According to French legal requirements,...
Continue Reading
A. Walker & Company Secures $50 Million for Housing Projects
A. Walker & Company Secures Major Capital Commitments A. Walker & Co. recently secured a significant capital commitment totaling up to $75 million, including an initial $50 million specifically set aside for affordable housing development. This funding is a critical step towards increasing the availability of multifamily housing that can effectively serve the needs of...
Continue Reading
ClorDiSys Enhances Sterilization Capabilities with Expansion
ClorDiSys Expands Sterilization Operations ClorDiSys Solutions, LLC has announced a significant expansion in its sterilization facilities, designed to address the growing demand for its chlorine dioxide-based sterilization services. This expansion includes the addition of new chambers, which will effectively double the company’s processing capacity. With the new...
Continue Reading
Star Equity's KBS Builders Secures Major Contracts Worth $5.2M
KBS Builders Secures Significant Commercial Contracts Star Equity Holdings, Inc. is excited to announce that its subsidiary, KBS Builders, has successfully signed two major contracts worth a total of $5.2 million. These contracts focus on the manufacturing of housing units, promising to contribute positively not only to KBS's growth but also to addressing the ongoing...
Continue Reading
Navigating the Startup Jungle: Break Free from Traps
Understanding the Existing Market Trap A fresh approach from the creators of Play Bigger reveals the hidden costs startups face. The new book titled The Existing Market Trap: A Primer presents a timely exploration into why many startups struggle to gain traction. Co-authors Al Ramadan, Christopher Lochhead, alongside new contributors Jason Wellcome and Mary Gr
Continue Reading